Annual report pursuant to Section 13 and 15(d)

Note 16 - Income Taxes (Tables)

v3.20.1
Note 16 - Income Taxes (Tables)
12 Months Ended
Dec. 31, 2019
Notes Tables  
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
   
As of December 31,
 
   
201
9
   
201
8
 
Deferred tax assets:
               
Net operating loss carryforwards
  $
31,966,658
    $
29,597,313
 
R&D credit carryforwards
   
9,150,580
     
9,067,874
 
AMT credit carryforward
   
310,620
     
621,240
 
Stock compensation
   
382,016
     
375,731
 
Intangibles
   
610,783
     
550,797
 
Disallowed interest expense
   
857,648
     
878,929
 
Temporary differences
   
333,728
     
480,888
 
Deferred tax assets before valuation allowance
   
43,612,033
     
41,572,772
 
Valuation allowance
   
(43,301,413
)
   
(40,951,532
)
Net deferred tax assets
  $
310,620
    $
621,240
 
Summary of Tax Credit Carryforwards [Table Text Block]
   
 
 
 
 
As of December 31, 201
9
 
Generated
 
Expiration
   
U.S.
Net
Operating
Loss
Carryforwards
   
U.S.
R&D
Credit
Carryforwards
 
2000
 
2020
    $
    $
71,713
 
2001
 
2021
     
     
39,128
 
2002
 
2022
     
     
5,350
 
2003
 
2023
     
     
2,905
 
2004
 
2024
     
     
22,861
 
2005
 
2025
     
     
218,332
 
2006
 
2026
     
     
365,541
 
2007
 
2027
     
     
342,898
 
2008
 
2028
     
     
531,539
 
2009
 
2029
     
     
596,843
 
2010
 
2030
     
     
1,094,449
 
2011
 
2031
     
     
1,950,744
 
2012
 
2032
     
18,850,484
     
468,008
 
2013
 
2033
     
37,450,522
     
681,772
 
2014
 
2034
     
34,088,874
     
816,116
 
2015
 
2035
     
25,073,846
     
492,732
 
2016
 
2036
     
15,581,209
     
262,257
 
2017
 
2037
     
     
387,892
 
2018
 
2038
     
     
197,547
 
2019
 
 N/A
     
11,138,102
     
213,065
 
Total carryforwards
    $
142,183,037
    $
8,761,692
 
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
   
201
9
   
201
8
 
   
Amount
   
%
   
Amount
   
%
 
Benefit at statutory rate
  $
(2,299,122
)
   
(21.0
)%
  $
(3,383,491
)
   
(21.0
)%
Adjustments to valuation allowance
   
2,355,947
     
21.5
%
   
2,458,580
     
15.3
%
Adjustments to R&D credit carryforwards
   
(82,706
)
   
(0.8
)%
   
975,840
     
6.1
%
Permanent items and other
   
26,588
     
0.3
%
   
(60,682
)
   
(0.3
)%
Provision (benefit) per financial statements
  $
707
     
 
    $
(9,753
)